Skip Ribbon Commands
Skip to main content
 
Search
Skip navigation links
About EBMT
Research
Education
Data Management
Quality Management
Members & Sponsors
Annual Meeting
Resources
Section contents
Skip navigation links
Non interventional prospective studies
Single diagnosis
More than one diagnosis
Not specific to a diagnosis
Retrospective studies
Single diagnosis
More than one diagnosis
Not specific to a diagnosis
Prospective clinical trials
Single diagnosis
More than one diagnosis
Publications
Nursing research
Transplant Activity Survey
Participate in Activity Survey
Documentation
Results
Publications
Contacts
> Home > Research > Retrospective studies > Single diagnosis
Single diagnosis

 

 

Acute Myelogenous Leukemia
 
WP study number:
8421023
Working Party:
Acute Leukemia WP
Full Title:
ivFB2 vs ivFB4 for allogeneic transplant in AML
Start Date:
2011 October
Key inclusion criteria:
Fludarabin, Busulphan, AML, Allogeneic transplanta
Study status:
Data Collection
Chief Investigator contact:
M Kharfan Dabaja
EBMT contact:
Leila Moukhtari
 
WP study number:
8421022
Working Party:
Acute Leukemia WP
Full Title:
Effect of post-remission chemotherapy before reduced intensity and non-myeloablative allogeneic HSCT for AML in 1st CR
 
Start Date:
2011 September
Key inclusion criteria:
Consolidation, Ara-C, RIC, Allo, AML 1st CR
Study status:
Data Collection
Chief Investigator contact:
Yeshurun Moshe
EBMT contact:
Leila Moukhtari
 
WP study number:
8421024
Working Party:
Acute Leukemia WP
Full Title:
Impact of Campath versus ATG after unrelated allogeneic stem cell transplantation with RIC as treatment for AML in CR1
Start Date:
2012 February
Key inclusion criteria:
Campath, ATG, T-cell depletion, AML, CR1 Allogeneic HSCT
Study status:
Data collection
Chief Investigator contact:
Baron Frédéric
EBMT contact:
Emmanuelle Polge
 
WP study number:
8421015
Working Party:
Acute Leukemia WP
Full Title:
Comparison of TBI/Cy vs Bu/Cy preparative regimens before allogeneic SCT in 1st relapse for AML
(amended in 02/2012)
Start Date:
2011 February
Key inclusion criteria:
AML, Resistante, Refractory, BuCY, TBI, Myeloablative
Study status:
Data collection
Chief Investigator contact:
Nagler Arnon
EBMT contact:
Emmanuelle Polge
 
WP study number:
8421021
Working Party:
Acute Leukemia WP
Full Title:
Survey on HSCT for Acute Promyelocytic Leukemia (APL/M3) in the ATO era
Start Date:
2011 April
Key inclusion criteria:
AML de Novo, APL/M3,
Study status:
Data collection
Chief Investigator contact:
Jaime Sanz & Jordi Esteve
 
EBMT contact:
Emmanuelle Polge
 
WP study number:
8421014
Working Party:
Acute Leukemia WP
Full Title:
Outcome of alloHSCT for AML with 11q23 (MLL) rearrangement
Start Date:
2010 November
Key inclusion criteria:
de novo AML, 11q23 abnormality, ALLO
Study status:
Paper in preparation
Chief Investigator contact:
Arnaud Pigneux
 
EBMT contact:
Betty Bouveur
 
WP study number:
8421019
Working Party:
Acute Leukemia WP
Full Title:
Retrospective comparison of allogeneic HCT outcomes of patients with acute myeloid leukemia (AML) transplanted at EM-BMT participating centers vs.  EBMT
Start Date:
2011 April
Key inclusion criteria:
de novo acute myeloid leukemia,  Allo-HSCT in CR1, match related donor,  myeloablative conditioning
Study status:
Paper in preparation
Chief Investigator contact:
Ali Bazarbachi
 
EBMT contact:
Betty Bouveur
 
WP study number:
8421020
Working Party:
Acute Leukemia WP
Full Title:
IV Busulfan in autologous HSCT
Start Date:
2011 June (amendment)
Key inclusion criteria:
AML, Autologous, IV Busulphan
Study status:
Paper in preparation
Chief Investigator contact:
Nagler Arnon
 
EBMT contact:
Betty Bouveur
 
WP study number:
8421012
Working Party:
Acute Leukemia WP
Full Title:
Retrospective study on the impact of molecular markers on the outcome of patients with AML autografted in CR
Start Date:
2010 July
Key inclusion criteria:
AML, Autologous HSCT, Molecular Marker, FLT3, NPM1
Study status:
Submited
Principal Investigator
Gorin Norbert-Claude
EBMT contact:
Polge Emmanuelle
 
Acute Lymphoblastic Leukemia
 
WP study number:
8421025
Working Party:
Acute Leukemia WP
Full Title:
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1)
Start Date:
2012 February
Key inclusion criteria:
ALL, Phi+, Allogeneic transplantation
Study status:
Data Collection
Chief Investigator contact:
Brissot Eolia
EBMT contact:
Leila Moukhtari
 
WP study number:
8421017
Working Party:
Acute Leukemia WP
Full Title:
Outcome of RIC MUD alloHSCT in ALL patients on behalf of the Acute Leukaemia Working Party (EBMT)
Start Date:
2001 March
Key inclusion criteria:
ALL, Allogeneic HSCT, Reduced Intensity Conditioning,  Unrelated Donor
Study status:
Data collection
Chief Investigator contact:
Medd  Patrick   & Peniket Andy
 
EBMT contact:
Emmanuelle Polge
 
Acute Leukemia (Acute Myelogenous & Lymphoblastic Leukemia)
 
WP study number:
8421016
Working Party:
Acute Leukemia WP
Full Title:
Second RIC allogeneic transplant as a rescue strategy for acute leukemia patients who relapse an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes
Start Date:
2011 February
Key inclusion criteria:
Acute Leukemia, Relapse, Reduce intensity conditioning,
Study status:
Data collection
Chief Investigator contact:
Mohamad Mohty
EBMT contact:
Polge Emmanuelle
 
WP study number:
8421013
Working Party:
Acute Leukemia WP
Full Title:
Clofarabine containing conditioning regimen for allo-SCT in AML/ALL patients
Start Date:
2010 December
Key inclusion criteria:
Acute Leukemia, Clofarabine, allogeneic HSCT
Study status:
Paper in preparation
Chief Investigator contact:
Chevallier Patrice
 
EBMT contact:
Polge Emmanuelle

 

Chronic Myeloid Leukemia - CML

WP study number:
42201033
Working Party:
CLWP
Full Title:
Retrospective analysis of the outcome of PH- bcr-abl CML patients after allogeneic HSCT
Start Date:
15-10-2008
End date: show only if study really stopped, otherwise hide this item
15-12-2010
Key inclusion criteria:
>18 years old; period 1997-2006; PH neg chromosome and bcr-abl negative
Study status:
Manuscript phase
Chief Investigator contact:
Henrike Thomssen
 
EBMT contact:
Anja Henseler
 

Chronic Lymphocytic Leukemia - CLL

WP study number:
42204421
Working Party:
CLWP
Full Title:
Data quality check in allogeneic CLL
Key inclusion criteria:
>18 years old; CLL
Study status:
In preparation
Chief Investigator contact:
Johannes Schetelig
EBMT contact:
Annelies Kleijne
 
Lymphoma
 
WP study number:
2009-R-01
Working Party:
Lymphoma WP
Full Title:
Outcome of ASCT failure in patients with mantle cell lymphoma, impact of allo salvage.
Start Date:
2011 October
Key inclusion criteria:
MCL, 18 - 70 yrs, autologous HSCT 2000-2009, no tandem procedure planned
(autoSCT/ alloSCT), PB as stem cell  source
Study status:
Data collection
Chief Investigator contact:
Sascha Dietrich, Peter Dreger
EBMT contact:
Hervé Finel
 
WP study number:
2010-R-10
Working Party:
Lymphoma WP
Full Title:
HTLV-1 Associated Adult T-Cell Leukemia/ Lymphoma. Comparison with antivirally or chemotherapy treated patients.
Start Date:
2011 August
Key inclusion criteria:
Recipients of autografts or allografts transplanted for ATL 1995-2009, age > 18 y.o.
HTLV-I +      
Study status:
Data collection
Chief Investigator contact:
Ali Bazarbachi, Kate Cwynarski
EBMT contact:
Hervé Finel
​
WP study number:
2010-R-01
Working Party:
Lymphoma WP
Full Title:
Autologous HSCT in Burkitt's lymphoma in the Rituximab era.
Start Date:
2011 November
Key inclusion criteria:
Burkitt, 18-65 yrs, 1st autologous HSCT (and 2nd planned), information about pre-ASCT  treatment (+/- Rituximab) available
Study status:
Data collection
Chief Investigator contact:
Osman Ahmed, Mahmoud Aljurf
EBMT contact:
Hervé Finel
​
 
WP study number:
2010-R-07
Working Party:
Lymphoma WP
Full Title:
Autologous HSCT for Enteropathy-Associated T-Cell Lymphoma.  
Start Date:
2010 April 
Key inclusion criteria:
EATCL, age > 18 y.o., autologous or allogeneic  HSCT 2000-2007
Study status:
Data collection 
Chief Investigator contact:
Esa Jantunen
EBMT contact:
Hervé Finel
​
 
WP study number:
2009-R-06
Working Party:
Lymphoma WP
Full Title:
Autologous & allogeneic transplants for extra-nodal NK/T lymphoma.
Start Date:
2010 July
Key inclusion criteria:
NK/T lymphoma, age > 18 y.o., previous autologous and/or allogeneic stem cell/bone marrow transplantation
Study status:
Data collection
Chief Investigator contact:
Christopher Fox
EBMT contact:
Hervé Finel
 
 
WP study number:
2010-R-11
Working Party:
Lymphoma WP
Full Title:
Paediatric Hodgkin Lymphoma
Start Date:
ASAP
Key inclusion criteria:
HL, age <18 y.o., 1st autologous HSCT 2000-2005
Study status:
Preparation
Chief Investigator contact:
Alexander Claviez
EBMT contact:
Hervé Finel
 
 

Myelodysplastic syndrome – MDS

Study 1
WP study number:
42205536
Working Party:
CLWP
Full Title:
Analysis of alloSCT in MDS and 5q- chromosomal abnormalities
Start Date:
1 March 2010
Key inclusion criteria:
>18 years old; MDS 5q-; alloSCT
Study status:
ongoing
Chief Investigator contact:
Laurent Garderet
EBMT contact:
Marijke Scholten
 
Study 2
WP study number:
42205540
Working Party:
CLWP
Full Title:
RIC vs standard conditioning in allo SCT for Myelofibrosis
Start Date:
01-12-2009
Key inclusion criteria:
Myelofibrosis at diagnosis and transplant
Study status:
Manuscript phase
Chief Investigator contact:
Nicolaus Kröger
 
EBMT contact:
Marijke Scholten
 

Multiple Myeloma - MM

WP study number:
42206632
Working Party:
CLWP
Full Title:
Comparison of alloSCT in rare myelomas with autoSCT in (other) myelomas
Start Date:
19-02-2010
End date: show only if study really stopped, otherwise hide this item
01-06-2011
Key inclusion criteria:
>18 years old; MM
Study status:
Manuscript phase
Chief Investigator contact:
Curly Morris
 
EBMT contact:
Anja van Biezen

 

 

 

​ ​​​

 

 News

 
EBMT Newsletter March 2012
07/03/2012
... Read more >>
Results of the EBMT Online elections 2012
​New chairperson of the Chronic Leukaemia and Late Effects Working Parties... Read more >>
Documentary entitled Surviving Amina
​A love story challenged by illness and death, an intimate diary on resilience and hope.... Read more >>
 

 Events